.png)
.png)
BIA welcomes Chancellor’s life sciences growth package
The UK Government has announced a package of investment and policy initiatives to support the continued growth of the sector following a meeting of the Chancellor, Jeremy Hunt MP, and industry leaders in Downing Street.
Coulter Partners announces Gerben van 't Klooster as chief development officer at TargED Biopharmaceuticals
Coulter Partners, is pleased to announce the placement of Gerben van 't Klooster as Chief Development Officer (CDO) of TargED Biopharmaceuticals.
Touchlight creates world’s largest DNA manufacturing facilities in London, UK
- Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines. Supplying many of the top biopharmaceutical companies in the world.
Discovery Park and EKC Group join forces to boost STEM careers in Kent
A partnership has been forged between Discovery Park and EKC Group, a further education provider, to inspire more of Kent’s young people to experience a career in science, technology, engineering and maths.
In2scienceUK, promoting diversity and inclusion within STEM
In2scienceUK is a charity that empowers young people from low-income backgrounds to reach their potential and progress to careers in Science, Technology, Engineering and Mathematics (STEM)
Madonna, mass consumption and microbes
In his guest blog, Dr Edward Green, CEO at NCIMB shares the potential of microbes to achieve some of the UN's Sustainable Development Goals and address global challenges.
New senior hire for the medical writing team at Boyds
Leading global drug development consultancy Boyds has made a new appointment to its medical writing team in response to rising demand for its services.
CEO Update - 22 May 2023
On Thursday I will be attending the bi-annual UK Life Science Council, the set piece meeting of the UK life science industry with the UK government. Thanks to months-long backroom work, by the BIA team and civil servants, I think the scene is set for a productive discussion on the Scale Up finance agenda, what we need to do to get clinical trials going again in the UK and how we can support the development of a skilled workforce in life science.
PharmEnable closes $7.5 million financing to develop next generation small molecule drugs
Funds will allow PharmEnable to advance and expand its portfolio of wholly owned and co-discovery projects around challenging targets in cancer and neurology
Coulter Partners places Board Director at IN8bio
Coulter Partners is pleased to announce the placement of Jeremy Graff, PhD to the Board of Directors of IN8bio, Inc., a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies.